There were 1,885 press releases posted in the last 24 hours and 439,456 in the last 365 days.

Horizon Pharma plc to Participate in Morgan Stanley 15th Annual Global Healthcare Conference

DUBLIN, Ireland, Aug. 24, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the Company will present at the Morgan Stanley 15th Annual Global Healthcare Conference at 10:30 a.m. ET on September 13, 2017 in New York City, NY.

The conference presentation will be webcast live and may be accessed by visiting Horizon's investor relations section of the website at http://ir.horizon-pharma.com.  A replay of the webcast will be available for the event.

About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs.  The Company markets 11 medicines through its orphan, rheumatology and primary care business units.  For more information, please visit www.horizonpharma.com.  Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Contacts:

Investors:
Tina Ventura  
Senior Vice President,
Investor Relations
investor-relations@horizonpharma.com   

Ruth Venning
Executive Director, 
Investor Relations
investor-relations@horizonpharma.com

U.S. Media:
Geoff Curtis
Senior Vice President,
Corporate Affairs & Chief Communications Officer
media@horizonpharma.com

Ireland Media:
Ray Gordon
Gordon MRM
ray@gordonmrm.ie

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.